Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part D Expected To Keep Protected Class Status Quo, Despite Bill Language

Executive Summary

Although legal language does not mirror current CMS guidance, industry observers are expecting little change when it comes to the concept of covering "all or substantially all" drugs in the six protected classes under Medicare Part D once provisions of the new Medicare law are enacted

You may also be interested in...



Six Protected Drug Classes Codified In Medicare Part D Under Draft Bill

Technical corrections bill could be passed in lame duck session after November elections.

Medicare Bill Allows Changes To Part D Protected Classes, Via Rule-Making

The new statutory requirement that Medicare drug plans cover all drugs in protected drug classes includes a hint of possible flexibility for interested stakeholders - the designated groups could be expanded or subtracted, though only through a formal regulatory process

FDA 2015 Budget Increase Proposal Leans On Food Safety User Fees

Food safety programs would get the largest increase in the White House’s proposed fiscal 2015 FDA budget, and increases in user fee programs are proposed as key drivers for the boost. The agency’s overall budget would grow $335 million to $4.7 billion in the proposal.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS049977

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel